Advanced cell tests now provide reliable insights into toxicity and biological behaviour for investigational molecules. Yet they can’t identify which tumours will best demonstrate your compound’s full clinical value in tomorrow’s treatment landscape.
An early clinical analysis puts preclinical data in the perspective of future medical needs. It helps guide tumor selection for animal studies and, ultimately, for phase 2 trial, while ruling out early costly clinical dead ends
A structured, step-by-step framework designed to uncover critical insights at the turning point between preclinical and clinical development.